Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Profit Outlook
Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Profit Outlook
We feel now is a pretty good time to analyse Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) business as it appears the company may be on the cusp of a considerable accomplishment. Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The US$4.9b market-cap company posted a loss in its most recent financial year of US$529m and a latest trailing-twelve-month loss of US$333m shrinking the gap between loss and breakeven. Many investors are wondering about the rate at which Apellis Pharmaceuticals will turn a profit, with the big question being "when will the company breakeven?" In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.
我們認爲現在是分析apellis pharmaceuticals股票的一個相當好的時機,因爲這家公司似乎即將取得重大成就。apellis pharmaceuticals是一家商業階段的生物製藥公司,專注於通過抑制補體系統來發現、開發和商業化治療化合物,用於自身免疫性和炎症性疾病。這家市值49億美元的公司在最近一個財政年度錄得了5.29億美元的虧損,最新的過去十二個月虧損爲3.33億美元,縮小了虧損與盈虧平衡之間的差距。許多投資者想知道apellis pharmaceuticals何時才能實現盈利,最關鍵的問題是「這家公司何時能盈虧平衡?」在本文中,我們將提及公司增長的預期以及分析師預計公司何時可盈利。
Consensus from 17 of the American Biotechs analysts is that Apellis Pharmaceuticals is on the verge of breakeven. They expect the company to post a final loss in 2024, before turning a profit of US$22m in 2025. Therefore, the company is expected to breakeven just over a year from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 68% is expected, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.
美國17家生物技術公司分析師的共識是apellis pharmaceuticals即將實現盈虧平衡。他們預計該公司將在2024年出現最終虧損,然後在2025年實現2200萬美元的盈利。因此,該公司預計將在一年多一點的時間內實現盈虧平衡。爲了滿足這一盈虧平衡日期,我們計算了公司必須實現的年增長率。結果顯示預期的平均年增長率爲68%,這是非常樂觀的。如果企業增長速度較慢,那麼實現盈利的時間將比預期晚。
![1724419983430](https://newsfile.futunn.com/public/NN-PersistNewsContentImage/7781/20240823/46983366-0-ce6a1ff7490984e96be9ce7d385afcfa.avif/big)
Underlying developments driving Apellis Pharmaceuticals' growth isn't the focus of this broad overview, however, bear in mind that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.
驅動apellis pharmaceuticals增長的基礎發展並非本次廣泛概述的重點,然而,請記住,總體來說,生物技術公司根據產品開發階段,現金流呈現不規律週期。這意味着,公司即將獲得早期投資的好處,即將迎來大幅增長率並不正常。
One thing we would like to bring into light with Apellis Pharmaceuticals is its debt-to-equity ratio of 173%. Typically, debt shouldn't exceed 40% of your equity, and the company has considerably exceeded this. A higher level of debt requires more stringent capital management which increases the risk around investing in the loss-making company.
我們想要指出的一件事是apellis pharmaceuticals的資產負債比達到了173%。通常,債務不應超過您的淨資產的40%,但這家公司明顯超過了這一比例。更高水平的債務要求更加嚴格的資本管理,增加了投資於這家虧損公司的風險。
Next Steps:
下一步:
There are too many aspects of Apellis Pharmaceuticals to cover in one brief article, but the key fundamentals for the company can all be found in one place – Apellis Pharmaceuticals' company page on Simply Wall St. We've also compiled a list of relevant aspects you should further examine:
Apellis Pharmaceuticals有太多的方面需要在一篇簡短的文章中涵蓋,但是該公司的關鍵基本面都可以在一個地方找到–Simply Wall St上的Apellis Pharmaceuticals介紹頁面。我們還編制了一個相關方面的列表,您應該進一步檢查:
- Valuation: What is Apellis Pharmaceuticals worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Apellis Pharmaceuticals is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Apellis Pharmaceuticals's board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
- 估值:Apellis Pharmaceuticals今天市值多少?未來的增長潛力已經被市場因素考慮在內了嗎?我們的免費研究報告中的內在價值信息圖表可以幫助可視化Apellis Pharmaceuticals是否已經被市場錯價。
- 管理團隊:一支經驗豐富的領導團隊增強了我們對企業的信心——看看誰坐在Apellis Pharmaceuticals董事會上,以及CEO的背景。
- 其他高表現的股票:是否有其他表現更好的股票並具有經過驗證的歷史記錄?查看這裏的免費列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
譯文內容由第三人軟體翻譯。